Back to Search
Start Over
Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor
- Source :
- Cancer immunology, immunotherapy : CII.
- Publication Year :
- 2022
-
Abstract
- Tumor immunotherapies have shown promising antitumor effects, especially immune checkpoint inhibitors (ICIs). However, only 12.46% of the patients benefit from the ICIs, the rest of them shows limited effects on ICIs or even accelerates the tumor progression due to the lack of the immune cell infiltration and activation in the tumor microenvironment (TME). In this study, we administrated a combination of Toll-like receptor 9 (TLR9) agonist CpG ODN and Transforming growth factor-β2 (TGF-β2) antisense oligodeoxynucleotide TIO3 to mice intraperitoneally once every other day for a total of four injections, and the first injection was 24 h after LLC cell inoculation. We found that the combination induced the formation of TME toward the enrichment and activation of CD8
- Subjects :
- Cancer Research
Oncology
Immunology
Immunology and Allergy
Subjects
Details
- ISSN :
- 14320851
- Database :
- OpenAIRE
- Journal :
- Cancer immunology, immunotherapy : CII
- Accession number :
- edsair.doi.dedup.....40b585bec3f3ea7cca2b9a0496f51ecf